Bronchiectasis
Conditions
Interventions
Group A:based on conventional clinical treatment including anti-infective and expectorant therapy.
Group B:Bronchoalveolar lavage with saline on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of 2 lobes, and a total volume of up to 180 ml.
Group C:Bronchoalveolar lavage with acetylcysteine solution in combination with saline on the basis of conventional clinical treatment, with a volume of 90 ml per target lung lobe, up to a maximum of
Sponsors
Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years, inclusive; 2. Chest CT suggestive of bronchiectasis; 3. Meet the criteria for an acute exacerbation of bronchiectasis with symptoms such as cough, sputum, chest tightness or wheezing, and c. Patients who meet the criteria for an acute exacerbation of bronchiectasis with symptoms of cough, sputum, chest tightness or wheezing and who consent to bronchoscopy with bronchoalveolar lavage; 4. Patients who agreed to participate in the study and signed an informed consent form;
Exclusion criteria
Exclusion criteria: 1. Severe cardiopulmonary diseases, coagulation disorders, poor tolerance to anaesthesia, psychiatric disorders or severe neuroses that are contraindications to bronchoscopy; 2. Intraoperative findings of decreased SPO2 or inability to tolerate bronchoscopy or inability to tolerate further bronchoalveolar lavage; 3. Inability to co-operate with the study for any reason or in the opinion of the investigator, inappropriate for inclusion in the study for other reasons; 4. Bronchoscopy of patients with significant intra-airway haemorrhage who may be at risk of exacerbation due to bronchoalveolar lavage; 5. Patients with acetylcysteine allergy; 6. Missing information;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to the first acute exacerbation;Time to the second acute exacerbation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of symptoms;Number of acute exacerbations;adverse effects;Re-treatment with bronchoalveolar lavage; | — |
Countries
China
Contacts
Public ContactZhongbo Chen
Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University
Outcome results
None listed